Ofatumumab versus Teriflunomide in Multiple Sclerosis
2020; Massachusetts Medical Society; Volume: 383; Issue: 6 Linguagem: Inglês
10.1056/nejmoa1917246
ISSN1533-4406
AutoresStephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen, Gıancarlo Comı, Jorge Correale, Patricia K. Coyle, Anne H. Cross, de Sèze, David Leppert, Xavier Montalbán, Krzysztof Selmaj, Heinz Wiendl, Cécile Kerloëguen, Roman Willi, Bingbing Li, Algirdas Kakarieka, Davorka Tomic, Alexandra Goodyear, Ratnakar Pingili, Dieter A. Häring, Prakash Krishnan, Martin Merschhemke, Ludwig Kappos, Pierre Labauge,
Tópico(s)Immunodeficiency and Autoimmune Disorders
ResumoOfatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.
Referência(s)